| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | |
|---|---|---|---|---|
| Collaboration and other revenue | 0 | - | 11 | |
| Research and development expense (includes related party amounts of 0 for the three and nine months ended september 30, 2025 and 1,775 and 2,025 for the three and nine months ended september 30, 2024, respectively) | 9.539 | 13.684 | 16.395 | |
| General and administrative expense | 4.25 | 4.963 | 5.875 | |
| Total operating expenses | 13.789 | 18.647 | 22.27 | |
| Loss from operations | -13.789 | -18.647 | -11.27 | |
| Other income | - | - | -0.008 | |
| Interest income | 0.133 | 0.233 | 0.692 | |
| Loss on warrant liability | -2.119 | -0.297 | - | |
| Other expense | 0.003 | - | - | |
| Total other income (loss) | -1.989 | -0.064 | 0.684 | |
| Net loss and comprehensive loss | -15.778 | -18.711 | -10.586 | |
| Net loss per common share, basic | -0.27 | -0.32 | -0.22 | |
| Net loss per common share, diluted | -0.27 | -0.32 | -0.22 | |
| Weighted-average shares of common stock outstanding, basic | 58,745,343 | 58,504,396 | 48,335,847 | |
| Weighted-average shares of common stock outstanding, diluted | 58,745,343 | 58,504,396 | 48,335,847 | |
BioAtla, Inc. (BCAB)
BioAtla, Inc. (BCAB)